Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Drug treatment of Parkinson's disease: is "polypharmacy" best?

Literature DB >> 8163984

Drug treatment of Parkinson's disease: is "polypharmacy" best?

P D Swanson¹.

Abstract

Entities: Disease

Mesh：

Substances：
Antiparkinson Agents

Year: 1994 PMID： 8163984 PMCID： PMC1072864 DOI： 10.1136/jnnp.57.4.401

Source DB: PubMed Journal: J Neurol Neurosurg Psychiatry ISSN： 0022-3050 Impact factor: 10.154

× No keyword cloud information.

23 in total

Review 1. Drug therapy of Parkinson's disease. An overview.

Authors: Y Mizuno
Journal: Eur Neurol Date: 1992 Impact factor: 1.710

2. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.

Authors: J W Tetrud; J W Langston
Journal: Science Date: 1989-08-04 Impact factor: 47.728

3. Third interim report of the nationwide collaborative study on the long-term effects of bromocriptine in the treatment of parkinsonian patients.

Authors: T Nakanishi; I Kanazawa; I Goto; M Iwata; H Kowa; T Mannen; Y Mizuno; H Nishitani; N Ogawa; A Takahashi
Journal: Eur Neurol Date: 1990 Impact factor: 1.710

4. Selegiline use to prevent progression of Parkinson's disease. Experience in 22 de novo patients.

Authors: T S Elizan; M D Yahr; D A Moros; M R Mendoza; S Pang; C A Bodian
Journal: Arch Neurol Date: 1989-12

5. Deprenyl effects on levodopa pharmacodynamics, mood, and free radical scavenging.

Authors: F Baronti; T L Davis; R C Boldry; M M Mouradian; T N Chase
Journal: Neurology Date: 1992-03 Impact factor: 9.910

6. A nation-wide collaborative study on the long-term effects of bromocriptine in patients with Parkinson's disease. First interim report in Japan.

Authors: T Nakanishi; Y Mizuno; I Goto; M Iwata; I Kanazawa; H Kowa; T Mannen; H Nishitani; N Ogawa; A Takahashi
Journal: Eur Neurol Date: 1988 Impact factor: 1.710

7. A nationwide collaborative study on the long-term effects of bromocriptine in patients with Parkinson's disease. The fourth interim report.

Authors: T Nakanishi; Y Mizuno; I Goto; M Iwata; I Kanazawa; H Kowa; T Mannen; H Nishitani; N Ogawa; A Takahashi
Journal: Eur Neurol Date: 1991 Impact factor: 1.710

8. Multi-center study of Parkinson mortality with early versus later dopa treatment.

Authors: S G Diamond; C H Markham; M M Hoehn; F H McDowell; M D Muenter
Journal: Ann Neurol Date: 1987-07 Impact factor: 10.422

9. Early combination of selegiline and low-dose levodopa as initial symptomatic therapy in Parkinson's disease. Experience in 26 patients receiving combined therapy for 26 months.

Authors: T S Elizan; D A Moros; M D Yahr
Journal: Arch Neurol Date: 1991-01

10. Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four-year period.

Authors: N Quinn; D Parkes; I Janota; C D Marsden
Journal: Mov Disord Date: 1986 Impact factor: 10.338

3 in total